Selected data models

You must log in to select data models for download or further analysis.

3 Search results.
Relevance Rating New first Old first

Visit 1 GIMEMA CML0408 NCT00769327 - Visit 1

- 9/20/21 - 1 form, 15 itemgroups, 150 items, 2 languages
Itemgroups: Previous chemotherapy, Comorbidities, Symptoms, Physical Examination, Complete Blood Count, Biochemistry, Serum Proteins, Electrocardiogram, Echocardiogram, Biopsie, Preservation of cellular samples, Cytogenetics, FISH (from bone marrow blood), Molecular Biology (peripheral blood), FISH (peripheral blood)
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 1 Form

Eligibility Lymphoma, Follicular NCT01902862

- 4/7/17 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01902862

Eligibility Lymphoma NCT00740415

- 4/7/17 - 1 form, 1 itemgroup, 10 items, 1 language
Itemgroup: Criteria
Rituximab, Bortezomib, Doxorubicin, Dexamethasone, and Chlorambucil Patients With Mantle Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00740415

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial